FDA reports of dosing errors with compounded semaglutide describe specific incidents. This analysis compared the mix of reports for compounded and FDA-approved GLP-1 products in the FDA Adverse Event Reporting System (FAERS) [1].
What was reported
Of 81,078 GLP-1 reports from 2018 to 2024, 707 involved compounded products. The reporting odds ratio was 48.92 for preparation errors (95% CI 12.63 to 189.60) and 19.00 for contamination (95% CI 4.24 to 85.03) [1].
Hospitalization also had higher reporting odds (2.35). Administration and dosing errors had lower reporting odds in this analysis. Those categories can be reported differently across products.
How to read an FDA safety report
A reporting odds ratio compares the relative prominence of an event in submitted reports. The database lacks a reliable count of everyone treated. FDA cautions that the reports alone cannot establish causation or establish one product's safety relative to another [2].
FDA separately describes concerns including errors and inadequate temperature control in some shipped compounded products [3]. Contact the dispensing pharmacist or prescriber if the instructions or condition of a shipment raise questions.